Beyond Air, Inc. (NASDAQ:XAIR) will release its fourth-quarter financial results after the closing bell on Tuesday, June 17.
Analysts expect the Garden City, New York-based company to report quarterly revenue of $1.39 million, compared to $470,000 a year earlier, according to data from Benzinga Pro.
On April 21, Beyond Air announced its NeuroNOS subsidiary was granted an FDA Orphan Drug Designation.
Beyond Air shares fell 3% to close at $0.1779 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can …